Investigators Discontinue Vibostolimab Combo in Extensive-Stage SCLC Trial

Fact checked by" Gina Mauro
News
Article

The overall survival data in the phase 3 KeyVibe-008 trial met the prespecified futility criteria.

In the double-blind KeyVibe-008 trial, 460 patients were assigned to receive frontline vibostolimab/pembrolizumab plus chemotherapy or atezolizumab plus chemotherapy.

In the double-blind KeyVibe-008 trial, 460 patients were assigned to receive frontline vibostolimab/pembrolizumab plus chemotherapy or atezolizumab plus chemotherapy.

Investigators will discontinue their evaluation of a fixed-dose coformulation including vibostolimab plus pembrolizumab (Keytruda) in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) as part of the phase 3 KeyVibe-008 trial (NCT05224141), according to a press release from the developer, Merck.1

Based on a pre-planned analysis, the data for overall survival (OS), the trial’s primary end point, fulfilled prespecified criteria for futility. Additionally, first-line treatment with the vibostolimab-based combination conferred a higher rate of adverse effects (AEs) and immune-related AEs vs atezolizumab (Tecentriq) in the comparator arm. Investigators are conducting a comprehensive analysis of these findings.

Patients enrolled on the KeyVibe-008 trial will be advised to halt treatment with vibostolimab/pembrolizumab and be offered the opportunity to switch to atezolizumab. Investigators intend to share their findings with the scientific community.

“[SCLC] remains a difficult disease to treat, as evident by the 7% 5-year survival rate and limited advancements in treatment options. Innovative research plays a critical role in improving our understanding to help patients achieve better outcomes, and while we hoped the results would be different, we remain committed to investigating novel approaches to treat this debilitating disease,” Marjorie Green, MD, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, stated in the press release.1

In the double-blind KeyVibe-008 trial, 460 patients were assigned to receive frontline vibostolimab/pembrolizumab plus chemotherapy or atezolizumab plus chemotherapy. Investigators administered pembrolizumab at 200 mg and vibostolimab at 200 mg intravenously every 3 weeks for 4 cycles in combination with etoposide plus carboplatin or cisplatin every 3 weeks for approximately 12 weeks followed by additional pembrolizumab/vibostolimab. In the comparator arm, patients received atezolizumab at 1200 mg every 3 weeks plus etoposide and carboplatin or cisplatin.

The trial’s primary end point was OS. Key secondary end points included progression-free survival, objective response rate, and duration of response based on blinded independent central review.

Patients 18 years and older with histologically or cytologically confirmed ES-SCLC defined as stage IV disease per American Joint Committee on Cancer, Eighth Edition were eligible for enrollment on the trial.2 Other requirements for study entry included having measurable disease based on RECIST v1.1 guidelines and a predicted life expectancy of more than 3 months.

Those who had prior treatment for SCLC, a live or live-attenuated vaccine within 30 days of beginning study treatment, or a known additional malignancy requiring treatment within 3 years of entry were ineligible for enrollment. Patients were also unable to enroll if they had active autoimmune disease requiring systemic therapy within 2 years of entry, an active infection requiring systemic therapy, an allogeneic tissue or solid organ transplant, major surgery within 3 weeks of entry, or symptomatic ascites or pleural effusion.

Developers are also assessing treatment with fixed-dose vibostolimab/pembrolizumab in patients with lung cancer as part of the phase 3 KeyVibe-003 trial (NCT04738487), phase 3 KeyVibe-006 trial (NCT05298423), and phase 3 KeyVibe-007 trial (NCT05226598). These studies have not undergone any design modifications following interim external data monitoring committee safety reviews. Comprehensive safety monitoring is ongoing for these trials.

In May 2024, developers announced the discontinuation of the phase 3 KeyVibe-010 trial (NCT05665595) assessing adjuvant vibostolimab/pembrolizumab for patients with resected high-risk stage IIB to IV melanoma.3 The trial was terminated after the primary end point of recurrence-free survival reached the prespecified futility criteria based on a pre-planned analysis. Additionally, most patients receiving vibostolimab/pembrolizumab discontinued the therapy after immune-mediated AEs.

References

  1. Merck provides update on phase 3 KeyVibe-008 trial evaluating an investigational fixed-dose combination of vibostolimab and pembrolizumab in patients with extensive- small cell lung cancer. News release. Merck. August 8, 2024. Accessed August 9, 2024. https://tinyurl.com/5fr4uwkt
  2. Pembrolizumab/​vibostolimab (MK-7684A) or atezolizumab in combination with chemotherapy in first line treatment of extensive-stage small cell lung cancer (MK-7684A-008, KEYVIBE-008). ClinicalTrials.gov. Accessed August 9, 2024. https://tinyurl.com/yaupe59s
  3. Merck provides update on phase 3 KeyVibe-010 trial evaluating an investigational coformulation of vibostolimab and pembrolizumab as adjuvant treatment for patients with resected high-risk melanoma. News release. Merck. May 13, 2024. Accessed August 9, 2024. https://tinyurl.com/2zeefcj2
Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Related Content
In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.

Durvalumab/Carboplatin/Etoposide Proves Tolerable in ES-SCLC

Tim Cortese
November 19th 2025
Article

Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Tim Cortese
October 31st 2025
Article

Combinations of antiangiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.